iCAD Inc., a leader in AI-powered breast health solutions, reported financial results for the first quarter ended March 31, 2025. The company achieved a total Annual Recurring Revenue $(ARR)$ of $10.7 million, marking an 18% increase compared to the previous year. Total revenues for the quarter amounted to $4.9 million. The gross profit margin was reported at 86%. In terms of business operations, iCAD successfully closed 92 total deals in Q1, including 19 ProFound Cloud deals. Additionally, the company reported a Non-GAAP Adjusted EBITDA income of $3 thousand for the first quarter of 2025, a notable improvement from a loss of $(1.1) million in the same period of 2024. iCAD stated it has sufficient cash resources, with cash and cash equivalents totaling $20.0 million as of March 31, 2025, to support its planned operations for at least the next 12 months without needing to raise additional funding.